Imiquimod clinical trials
Also written Aldara and Zyclara.
How each study uses Imiquimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Imiquimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Feb 1997 · ALDARA · NDA 020723 (FDA, Drugs@FDA)
- European Union
- 18 Sept 1998 · Aldara · EMEA/H/C/000179 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
120 studies that test it; most in 2008 (16)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 10 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 16 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 93
Graceway Pharmaceuticals, LLC (10) · MEDA Pharma GmbH & Co. KG (8) · The University of Hong Kong (4) · Maastricht University Medical Center (4) · University Hospital Tuebingen (3) · Medical University of Graz (3) · Medical University of Vienna (3) · University of Michigan (2)
Often tested with
Tested in the same studies.
Fluorouracil (5) · Pembrolizumab (2) · Cyclophosphamide (2) · Candida albicans Antigen Injection (1) · Histamine phosphate (1) · Histamine (1) · Human Papillomavirus Recombinant Vaccine nonavalent (1) · Human Papillomavirus Tumor Antigen Vaccine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Imiquimod.
- Dec 2026Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with ImiquimodPhase 4 · Barretos Cancer Hospital
- Jun 2027Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis FungoidesEarly Phase 1 · Northwestern University
- Jun 2027Dermal Priming in Enhancing Vaccine ImmunogenicityNot applicable · Cambridge University Hospitals NHS Foundation Trust
- Oct 2027Topical Imiquimod Treatment of Oral DysplasiaPhase 1/2 · University of Southern California
Studies
Open first, then newest update. How each study uses Imiquimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 123
- Dermal Priming in Enhancing Vaccine ImmunogenicityRecruitingNot applicableCambridge University Hospitals NHS Foundation TrustNCT07925996Written as Imiquimod (topical use)How we know
- Basal Cell Carcinoma Chemoprevention TrialRecruitingPhase 3VA Office of Research and DevelopmentNCT05212246Written as 5% Imiquimod creamHow we know
- Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma PatientsNot yet recruitingPhase 1/2Centre Leon BerardNCT07679841Written as Imiquimod 5% creamHow we know
- Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis FungoidesRecruitingEarly Phase 1Northwestern UniversityNCT05838599Written as ImiquimodHow we know
- Topical Imiquimod Treatment of Oral DysplasiaRecruitingPhase 1/2University of Southern CaliforniaNCT07210775Written as Imiquimod (topical use)How we know
- Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with ImiquimodRecruitingPhase 4Barretos Cancer HospitalNCT06356012Written as ImiquimodHow we know
- Deep Phenotyping of Cutaneous Lupus ErythematosusRecruitingNot applicableCentre for Human Drug Research, NetherlandsNCT06411106Written as IMIQUIMOD cream 50mg/gHow we know
- CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsRecruitingPhase 1OX2 TherapeuticsNCT06305910Written as Treatment with CD200AR-LHow we know
- Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the FaceCompletedPhase 3Nantes University HospitalNCT01720407Written as Imiquimod cream + surgeryHow we know
- Investigating the Effect of Topical Imiquimod on Sebaceous HyperplasiaCompletedPhase 4University of MichiganNCT06840470Written as Imiquimod 5% Topical CreamHow we know
- Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaCompletedEarly Phase 1Mayo ClinicNCT03276832Written as ImiquimodHow we know
- Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With ImiquimodTerminatedPhase 1James FelkerNCT01795313Written as ImiquimodHow we know
- A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell CarcinomaCompletedPhase 2Melanoma Institute AustraliaNCT03534947Written as ImiquimodHow we know
- Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin LesionsCompletedPhase 3AIDS Malignancy ConsortiumNCT02059499Written as imiquimodHow we know
- Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial NeoplasiaCompletedEarly Phase 1National Cancer Institute (NCI)NCT03196180Written as ImiquimodHow we know
- Immunologic Profile of Chronically Photodamaged SkinCompletedPhase 1University of MichiganNCT02889159Written as imiquimod 5% creamHow we know
- Neoadjuvant Imiquimod Immunotherapy for Oral CancerCompletedEarly Phase 1Medical University of South CarolinaNCT04883645Written as Imiquimod 5% CreamHow we know
- Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsCompletedPhase 3AIDS Malignancy ConsortiumNCT02135419Written as imiquimodHow we know
- Radiotherapy or Imiquimod in Complex Lentigo MalignaCompletedPhase 3Melanoma and Skin Cancer Trials LimitedNCT02394132Written as ImiquimodHow we know
- Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)CompletedPhase 2Yale UniversityNCT02864147Written as ImiquimodHow we know
See all 123 studies that test Imiquimod →
Given beside what is tested · 21 — Imiquimod is usual care or a partner of the new treatment
- IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade AstrocytomasNot yet recruitingPhase 2German Cancer Research CenterNCT07888647Written as Imiquimod 5 % CreamHow we know
- Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell CarcinomaRecruitingPhase 1/2Instituto Oncológico Dr RosellNCT07251413Written as Topical imiquimodHow we know
- Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02600949Written as ImiquimodHow we know
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedPhase 1Toray Industries, IncNCT03872947Written as Imiquimod CreamHow we know
- Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and ImiquimodTerminatedPhase 2Beth Israel Deaconess Medical CenterNCT00799110Written as imiquimodHow we know
- Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedPhase 1/2Stemline Therapeutics, Inc.NCT02078648Written as ImiquimodHow we know
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of ItchWithdrawnNot applicableAalborg UniversityNCT03943407Written as Zyclara 3.75 % Topical CreamHow we know
- Dendritic Cell Vaccine for Children and Adults With SarcomaCompletedPhase 1Macarena De La Fuente, MDNCT01803152Written as ImiquimodHow we know
- Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)CompletedPhase 2Inovio PharmaceuticalsNCT03180684Written as Imiquimod 5% CreamHow we know
- Coadministration of GA2 Sporozoites With AdjuvantsStatus unknownEarly Phase 1Leiden University Medical CenterNCT05468606Written as ImiquimodHow we know
- Dendritic Cell (DC) Vaccine for Malignant Glioma and GlioblastomaCompletedPhase 1Macarena De La Fuente, MDNCT01808820Written as ImiquimodHow we know
- A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownPhase 1Xiangya Hospital of Central South UniversityNCT04072900Written as Imiquimod 5% Topical CreamHow we know
- H5N1 With or Without Topical Aldara in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03472976Written as ImiquimodHow we know
- Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain TumorCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT01171469Written as ImiquimodHow we know
- Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung CancerCompletedPhase 2UbiVacNCT01909752Written as ImiquimodHow we know
- Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.Status unknownNot applicableSeoul St. Mary's HospitalNCT03206138Written as GX-188E, ImiquimodHow we know
- Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of MelanomaCompletedPhase 1University of VirginiaNCT01264731Written as ImiquimodHow we know
- Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSILTerminatedPhase 1GenticelNCT02689726Written as AldaraHow we know
- Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic TherapyTerminatedPhase 4Tennessee Clinical Research CenterNCT01203878Written as ImiquimodHow we know
- Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous LeishmaniasisCompletedPhase 2Foundation FaderNCT01380314Written as Miltefosine + ImiquimodHow we know
Showing 20 of 21.
As the comparator · 10 — what is tested is compared with Imiquimod
- Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%CompletedPhase 4LEO PharmaNCT01926496Written as Imiquimod Cream, 5%How we know
- Gene and Protein Expression Profiles After Treatment of Actinic KeratosesStatus unknownPhase 2Ismail GögenurNCT05740969Written as ImiquimodHow we know
- Efficacy of Tazarotene in Treatment of Verruca PlanaStatus unknownPhase 2Zagazig UniversityNCT05314127Written as ImiquimodHow we know
- Efficacy and Tolerability of Topical LFX453 for External Genital WartsCompletedPhase 2Novartis PharmaceuticalsNCT02482428Written as AldaraHow we know
- Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic KeratosisCompletedPhase 3Teva Pharmaceuticals USANCT01686152Written as Zyclara®How we know
- Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled StudyStatus unknownPhase 3Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo FabbriNCT03901690Written as Imiquimod 5% creamHow we know
- Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant RecipientsTerminatedPhase 4Medical University of ViennaNCT01538901Written as imiquimod 5% creamHow we know
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453CompletedPhase 1Novartis PharmaceuticalsNCT02052687Written as ImiquimodHow we know
- Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.CompletedPhase 1Taro Pharmaceuticals USANCT01788007Written as Zyclara® (imiquimod) Topical Cream 3.75%How we know
- Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo MalignaCompletedNot applicableUniversity of UtahNCT00707174Written as Imiquimod CreamHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
- Dermal Priming in Enhancing Vaccine ImmunogenicityNov 9, 2026NCT07925996
Codes
What other systems call Imiquimod · ClinicalTrials.gg INT006684
- MeSH (NLM) D000077271ImiquimodConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P1QW714R7MIMIQUIMODConfirmed FDA, NLM, Wikidata
- RxNorm 59943Confirmed FDA, Wikidata
- Wikidata Q423417imiquimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1431ImiquimodOne source FDA
- DrugBank DB00724One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077271 | Imiquimod | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P1QW714R7M | IMIQUIMOD | Confirmed FDA, NLM, Wikidata |
| RxNorm | 59943 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423417 | imiquimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1431 | Imiquimod | One source FDA |
| DrugBank | DB00724 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.